Acadia Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Acadia Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Acadia Pharmaceuticals Inc Strategy Report
- Understand Acadia Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Acadia Pharmaceuticals Inc (Acadia) discovers, develops, and commercializes small molecule drugs for the treatment of central nervous system (CNS) disorders. The company’s marketed product Nuplazid (pimavanserin) is an FDA-approved drug for the treatment of Parkinson’s disease psychosis. It's pipeline includes pimavanserin for the treatment of various indications which include Schizophrenia, Major Depressive Disorder (MDD), dementia-related psychosis (DRP), and trofinetide for the treatment of Rett Syndrome. The company markets its product in the US. It has operational presence in Denmark, Switzerland, and the UK. Acadia is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12830 El Camino Real, Suite 400, San Diego, California, 92130
Website
acadia.com
Telephone
1 858 5582871
No of Employees
597
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACAD (NASD)
Revenue (2022)
$726.4M
40.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
71.6%
(2022 vs 2021)
Market Cap*
$2.8B
Net Profit Margin (2022)
XYZ
79.8%
(2022 vs 2021)
* As of and is in US$
Acadia Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed: | Nuplazid |
| DAYBUE (trofinetide) | |
| Nuplazid | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company acquired Levo Therapeutics, Inc. |
| 2022 | New Products/Services | In October, the company announced the launch of Rett Revealed, a new awareness campaign. |
| 2022 | Contracts/Agreements | In January, the company and Stoke Therapeutics, Inc entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. |
Competitor Comparison
| Key Parameters | Acadia Pharmaceuticals Inc | Cannabis Science Inc | Eisai Inc | Forest Laboratories LLC | Otsuka Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Japan |
| City | San Diego | Irvine | Nutley | New York City | Chiyoda-ku |
| State/Province | California | California | New Jersey | New York | Tokyo |
| No. of Employees | 597 | - | - | - | 5,827 |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen R. Biggar, M.D., Ph.D. | Chairman | Executive Board | 2016 | 51 |
| Stephen R. Davis | President; Director; Chief Executive Officer | Executive Board | 2015 | 61 |
| Mark C. Schneyer | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 48 |
| Brendan P. Teehan | Chief Operating Officer; Head - Commercial; Executive Vice President | Senior Management | 2021 | 53 |
| Jennifer J. Rhodes | Secretary; Executive Vice President; Chief Legal Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward